Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of BAN0805 (ABBV-0805) for the treatment of Parkinson's disease

Trial Profile

A study of BAN0805 (ABBV-0805) for the treatment of Parkinson's disease

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs BAN 0805 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors AbbVie
  • Most Recent Events

    • 11 Feb 2019 According to a BioArctic media release, the company entered into a strategic alliance with AbbVie, under which ABBVie is responsible for the clinical development of ABBV-0805.
    • 11 Feb 2019 According to a BioArctic media release, the company has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805 (formerly- BAN-0805).
    • 01 Nov 2018 According to a BioArctic media release, the company expects to initiate this study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top